Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 009 JPY -0.79% Market Closed
Market Cap: 30.8B JPY
Have any thoughts about
Daito Pharmaceutical Co Ltd?
Write Note

Daito Pharmaceutical Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Daito Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Daito Pharmaceutical Co Ltd
TSE:4577
Cash & Cash Equivalents
ÂĄ4.7B
CAGR 3-Years
13%
CAGR 5-Years
16%
CAGR 10-Years
0%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash & Cash Equivalents
ÂĄ859B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
2%
Daiichi Sankyo Co Ltd
TSE:4568
Cash & Cash Equivalents
ÂĄ707.7B
CAGR 3-Years
9%
CAGR 5-Years
19%
CAGR 10-Years
15%
Otsuka Holdings Co Ltd
TSE:4578
Cash & Cash Equivalents
ÂĄ515.1B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash & Cash Equivalents
ÂĄ462.9B
CAGR 3-Years
34%
CAGR 5-Years
21%
CAGR 10-Years
16%
Astellas Pharma Inc
TSE:4503
Cash & Cash Equivalents
ÂĄ293B
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
-4%
No Stocks Found

Daito Pharmaceutical Co Ltd
Glance View

Market Cap
30.7B JPY
Industry
Pharmaceuticals

Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Intrinsic Value
2 429.67 JPY
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Daito Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
4.7B JPY

Based on the financial report for Aug 31, 2024, Daito Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 4.7B JPY.

What is Daito Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
0%

Over the last year, the Cash & Cash Equivalents growth was 17%. The average annual Cash & Cash Equivalents growth rates for Daito Pharmaceutical Co Ltd have been 13% over the past three years , 16% over the past five years .

Back to Top